Indoco Remedies

Indoco Remedies Financial Leverage

The Financial Leverage (Equity Multiplier) of Indoco Remedies (INDOCO.NS) as of Oct 18, 2026 is 2.76. In the previous year, Financial Leverage (Equity Multiplier) was 2.38 — a change of 16.12% (higher).

Financial Leverage

2.76

YoY

16.12%

Last updated:

Financial Leverage (Equity Multiplier) of Indoco Remedies is 2026 2.76 . Financial Leverage (Equity Multiplier) of Indoco Remedies was 2025 2.38 . It decreases by 16.12% higher compared to the previous year.

The Indoco Remedies Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2019
1.90 INR
Jan 1, 2020
1.87 INR
Jan 1, 2021
1.71 INR
Jan 1, 2022
1.64 INR
Jan 1, 2023
1.61 INR
Jan 1, 2024
1.93 INR
Jan 1, 2025
2.38 INR
Jan 1, 2026
2.76 INR
The Indoco Remedies Financial Leverage history
YEARFinancial LeverageYoY
2.76+16.12%
2.38+23.04%
1.93+19.83%
1.61-1.83%
1.64-3.94%
1.71-8.61%
1.87-1.74%
1.90+3.97%
1.83-0.30%
1.84+11.38%
1.65+1.20%
1.63+2.15%
1.60—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Indoco Remedies Stock analysis

What does Indoco Remedies do? Indoco Remedies Ltd, listed on the National Stock Exchange of India with ticker INDOCO.NS and ISIN INE873D01024, is a pharmaceutical company headquartered in Mumbai, India. The company operates within the Health Care sector, specifically in the Pharmaceuticals industry. It employs 6,101 full-time employees and went public via an IPO on January 7, 2005. Indoco Remedies Ltd focuses on the manufacturing and marketing of formulations, including finished dosage forms and active pharmaceutical ingredients (APIs). The company serves multiple therapeutic categories such as diabetology, respiratory care, stomatology, women's health, nutritional products, gastroenterology, cardiology, metabolic disorders, and primary care medicine. Its product portfolio includes brands like Cyclopam, Sensodent-K, Karvol Plus, Sensoform, Cital UTI, Kidodent, Rexidin M, Lignox A, Dentogel, Aloja, Homide, Renolen, Noxa, Dexoren - S, Aloja M, ATM, Febrex Plus, Sensodent-KF, SM Fibro, MCBM 69, Cal Aid, Snowdent, Dropizin, Zincoren, Coloferrin, Bfloren, RR Sensoform Dental, Mofloren-D, and Tuspel. The company caters to both domestic and international markets. Indoco Remedies Ltd has subsidiaries including Xtend Industrial Designers and Engineers Pvt Ltd, Indoco Remedies Czech sro, and Indoco Remedies UK Limited. The company's website is https://www.indoco.com/. Indoco Remedies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Indoco Remedies stock

Financial Leverage (Equity Multiplier) of Indoco Remedies is 2.76 in 2026.

Financial Leverage (Equity Multiplier) of Indoco Remedies changed from 2.38 to 2.76, representing a 16.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Indoco Remedies since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Indoco Remedies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Indoco Remedies

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Indoco Remedies